MD — Pediatrix Medical Group, Inc.

Summary of Pediatrix Medical Group, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Adjusted EBITDA: $66 million for Q4 2025, aligning with upwardly adjusted guidance; full-year adjusted EBITDA reached $276 million.
• Revenue: Consolidated revenue decreased due to a $26 million drop from non-same unit activity, despite a 4% same unit growth. Overall patient service volumes declined by nearly 3%.
• Pricing: Same unit pricing increased by just under 7%, driven by strong revenue cycle management (RCM) collections and favorable payer mix.
• Operating Cash Flow: Generated $115 million in Q4, down from $135 million year-over-year.
• Share Repurchase: Deployed $64 million to buy back 2.9 million shares, leaving approximately 83 million shares outstanding.
• Cash Position: Ended the quarter with $375 million in cash and net debt of $220 million, resulting in a net leverage of just under 1x.

2. Strategic Updates and Business Highlights

• Leadership Changes: New leaders were appointed in key areas to enhance care quality.
• Physician Incentive Programs: Introduced two new programs to align physician compensation with company performance, including stock price tracking bonuses.
• Growth Opportunities: Focus on expanding telemedicine capabilities and increasing presence in OB hospital medicine, leveraging existing hospital relationships.

3. Forward Guidance and Outlook

• 2026 Adjusted EBITDA Guidance: Expected to be between $280 million and $300 million, a 5% increase from 2025 at the midpoint.
• Revenue Projection: Anticipated full-year revenue of approximately $1.9 billion, consistent with 2025.
• G&A Expense Outlook: Forecasted to decrease slightly to between $230 million and $240 million, down from $241 million in 2025.

4. Bad News, Challenges, or Points of Concern

• Volume Declines: Notable decline in patient volumes across all service lines, attributed to tough year-over-year comparisons.
• Payer Mix Risks: Potential negative impact from the expiration of ACA subsidies, though the exact effects are difficult to quantify.
• Operational Challenges: The company acknowledged the difficulty in maintaining volume and pricing stability in the face of changing market dynamics.

5. Notable Q&A Insights

• Revenue Drivers: Management indicated that the 2026 revenue guidance assumes flat volume and pricing, with no significant growth expected.
• Variable Compensation Concerns: Questions arose about the impact of variable compensation on earnings, with management indicating that changes to compensation structures are aimed at better alignment rather than smoothing effects.
• Market Conditions: Management remains cautious about potential changes in government policies affecting payer mix and enrollment, stating they are closely monitoring the situation.

Overall, Pediatrix Medical Group reported solid financial results for Q4 2025 but faces challenges with declining patient volumes and potential risks related to payer mix. The company remains optimistic about growth opportunities and strategic initiatives aimed at enhancing care quality and operational efficiency.